With generic competition heating up, Vas Narasimhan outlines Novartis' growth plans at R&D day

Max Gelman

Senior Editor

Thursday marks Novartis’ annual R&D day, and with it comes CEO Vas Narasimhan’s attempt to spotlight the company’s pipeline strategy and emerging stars.

The biggest …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

With generic competition heating up, Vas Narasimhan outlines Novartis' growth plans at R&D day

Max Gelman

Senior Editor

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Biopharma begins to contemplate an RFK Jr.-influenced FDA if Trump wins

Novo Nordisk claims late-stage MASH victory, continuing GLP-1's expansion

Biogen brings in medical chief as CFO plans retirement; MacroGenics CEO announces departure

Q&A: Jade CEO talks about reverse merger and IgAN drugs

Exclusive: Blood stem cell therapy maker Garuda gets new CEO, adds $47M

BMS, J&J and AstraZeneca plea with appeals court to overturn drug price negotiations

With gener­ic com­pe­ti­tion heat­ing up, Vas Narasimhan out­lines No­var­tis' growth plans at R&D day

Senior Editor

Sign up to read this article for free.

more like this

Viridian Therapeutics

Waltham, MA, USA

With generic competition heating up, Vas Narasimhan outlines Novartis' growth plans at R&D day